THE IMPACT OF PARTICIPATION OF PATIENTS WITH CARDIOVASCULAR DISEASES IN THE GOVERNMENT PROGRAM “AFFORDABLE MEDICINES” ON THEIR ADHERENCE
DOI:
https://doi.org/10.32782/2226-2008-2026-1-15Keywords:
adherence, Affordable Medicines program, cardiovascular diseases, reimbursementAbstract
Introduction. High drug costs are one of the main barriers to achieving adherence, which jeopardizes the effectiveness of pharmacotherapy for chronic diseases. The general conclusion of a number of studies indicates a shortage of methods for increasing adherence. In order to reduce the financial burden on patients and increase the availability of medicines in Ukraine, the National Prescription Drug Cost Reimbursement Affordable Medicines Program (AMP) was launched. In 2018, the AMP received positive feedback on various criteria, but its impact on patient adherence hasn’t been studied. The aim of the study was to examine the impact of participation of patients with cardiovascular diseases (CVD) in the AMP on their adherence and to develop proposals for increasing adherence. Results. Against the background of the overall low adherence of patients with CVD, the adherence of patients participating in the AMP was higher. The study found a weak, significant positive correlation (r = 0.194; p ≤ 0.05) between patients’ participation in the AMP and their level of adherence. Study results don’t allow us to establish a clear dependence on the type of CVD and the adherence level of patients. Conclusion. The results of the study demonstrated a significant positive effect of CVD patients’ participation in the AMP on their adherence. The AMP may be an important tool for increasing adherence by expanding the range of drugs for the treatment of CVD through fixed combinations in a “single” pill that will meet all current guidelines for the provision of medical care for CVD, especially arterial hypertension.
References
Maidanyk RA. Dostup do likarskykh zasobiv v Ukraini: pryntsyp spivrobitnytstva i yurydychna model farmatsevtychnoho rynku [Access to medicines in Ukraine: the principle of cooperation and the legal model of the pharmaceutical market]. Pravo i hromadianske suspilstvo. 2014;1(6). (In Ukrainian). Available from: http://lcslaw.knu.ua/index.php/arkhivnomeriv/1-6-2014/item/156-dostup-do-likarskykh-zasobiv-v-ukraini-pryntsyp-spivrobitnytstva-i-iurydychna-modelfarmatsevtychnoho-rynku-maidanyk-r-a.
Prohrama “Dostupni liky” [The program “Accessible Medicines”]. Natsionalna sluzhba zdorovia Ukrainy. 2021. (In Ukrainian). Available from: https://edata.e-health.gov.ua/ogoloshennya-pro-ukladennya-dogovoriv/dostupni-liky.
Miller TA. Health literacy and adherence to medical treatment in chronic and acute illness: a meta-analysis. Patient Educ Couns. 2016;99(7):1079–1086. DOI: 10.1016/j.pec.2016.01.020.
Kardas P, Bago M, Barnestein-Fonseca P, et al. Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges. Front Pharmacol. 2022;13:944829. DOI: 10.3389/fphar.2022.944829.
Agh T, Hadziabdic MO, Garuoliene K, et al. POSC222 Eureca – Exploring Reimbursement Models for Medication Adherence Enhancing Interventions in European Countries: A Survey Protocol. Value in Health. 2022;25(1):S151. Available from: https://www.valueinhealthjournal.com/article/S1098-3015(21)02532-8/fulltext.
Ágh T, Hiligsmann M, Borah B, et al. Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report. Value in Health. 2024;27(2):133–142. Available from: https://www.valueinhealthjournal.com/article/S1098-3015(23)06192-2/fulltext.
Alqarni AM, Alrahbeni T, Qarni AA, et al. Adherence to diabetes medication among diabetic patients in the Bisha governorate of Saudi Arabia – a cross-sectional survey. Patient Prefer Adherence. 2018;13:63–71. DOI: 10.2147/PPA.S176355.
Panahi S, Rathi N, Hurley J, Sundrud J, Lucero M, Kamimura A. Patient Adherence to Health Care Provider Recommendations and Medication among Free Clinic Patients. J Patient Exp. 2022;9. DOI: 10.1177/23743735221077523.
Abbas S, Noor M, Masood AJ, et al. Analysis of medication adherence of chronic hypertensive patients in Pakistani community via open survey method. Explor Med. 2024;5:674–683. DOI: 10.37349/emed.2024.00248.
Asgedom SW, Atey TM, Desse TA. Antihypertensive medication adherence and associated factors among adult hypertensive patients at Jimma University Specialized Hospital, southwest Ethiopia. BMC Res Notes. 2018;11(1):27. DOI: 10.1186/s13104-018-3139-6.
Després F, Forget A, Kettani FZ, Blais L. PHP44 – Impact of Drug Reimbursement Modalities on Treatment Adherence in Patients Covered by Private Drug Insurance. Value in Health. 2014;17(3):A17. Available from: https://www.valueinhealthjournal.com/article/S1098-3015(14)00159-4/fulltext.
Aziz H, Hatah E, Bakry MM, Islahudin F. How payment scheme affects patients’ adherence to medications? A systematic review. Patient Prefer Adherence. 2016;10:837–850. DOI: 10.2147/PPA.S103057.
Prohrama “Dostupni liky”: Rezultaty i rekomendatsii dlia prohresu v dosiahnenni vsezahalnoho okhoplennia posluhamy okhorony zdorovia [The program “Accessible Medicines”: Results and recommendations for progress in achieving universal coverage of health care services]. Kyiv; 2018. 41 p. (In Ukrainian). Available from: https://moz.gov.ua/uploads/1/8324-policy_dialogue_vf_ukr.pdf.
Lukina Yu.V. The Moriscos-Green scale: The pros and cons of universal test, correction of mistakes. Rational Pharmacotherapy in cardiology. 2016;12(1):63–65. DOI: 10.20996/1819-6446-2016-12-1-63-65.
Kim J, Combs K, Downs J, Tillman F. Medication Adherence: The Elephant in the Room. US Pharm. 2018;43(1):30–34. Available from: https://www.uspharmacist.com/article/medication-adherence-the-elephant-in-the-room.
